Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC
NCT07509099Phase 3Recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of KL-140 in head and neck squamous cell carcinoma (HNSCC) (2 arms). Primary endpoint: Progression Free Survival at 51 months. Started Sep 2026; status: recruiting.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07509099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509099.